137 related articles for article (PubMed ID: 35849943)
1. The strategic roles of four enzymes in the interconnection between metabolism and oncogene activation in non-small cell lung cancer: Therapeutic implications.
Icard P; Simula L; Fournel L; Leroy K; Lupo A; Damotte D; Charpentier MC; Durdux C; Loi M; Schussler O; Chassagnon G; Coquerel A; Lincet H; De Pauw V; Alifano M
Drug Resist Updat; 2022 Jul; 63():100852. PubMed ID: 35849943
[TBL] [Abstract][Full Text] [Related]
2. Why may citrate sodium significantly increase the effectiveness of transarterial chemoembolization in hepatocellular carcinoma?
Icard P; Simula L; Wu Z; Berzan D; Sogni P; Dohan A; Dautry R; Coquerel A; Lincet H; Loi M; Fuks D
Drug Resist Updat; 2021 Dec; 59():100790. PubMed ID: 34924279
[TBL] [Abstract][Full Text] [Related]
3. How Phosphofructokinase-1 Promotes PI3K and YAP/TAZ in Cancer: Therapeutic Perspectives.
Simula L; Alifano M; Icard P
Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35626081
[TBL] [Abstract][Full Text] [Related]
4. IRS4 promotes the progression of non-small cell lung cancer and confers resistance to EGFR-TKI through the activation of PI3K/Akt and Ras-MAPK pathways.
Hao P; Huang Y; Peng J; Yu J; Guo X; Bao F; Dian Z; An S; Xu TR
Exp Cell Res; 2021 Jun; 403(2):112615. PubMed ID: 33894221
[TBL] [Abstract][Full Text] [Related]
5. Functional cooperation between HIF-1α and c-Jun in mediating primary and acquired resistance to gefitinib in NSCLC cells with activating mutation of EGFR.
Meng S; Wang G; Lu Y; Fan Z
Lung Cancer; 2018 Jul; 121():82-90. PubMed ID: 29858032
[TBL] [Abstract][Full Text] [Related]
6. Fructose-1,6-bisphosphate promotes PI3K and glycolysis in T cells?
Icard P; Alifano M; Donnadieu E; Simula L
Trends Endocrinol Metab; 2021 Aug; 32(8):540-543. PubMed ID: 34016523
[TBL] [Abstract][Full Text] [Related]
7. Combined use of PI3K and MEK inhibitors synergistically inhibits lung cancer with EGFR and KRAS mutations.
Jiang ZB; Huang J; Xie C; Li X; Liu L; He J; Pan H; Huang L; Fan XX; Yao XJ; Xie Y; Li N; Liu L; He JX; Leung EL
Oncol Rep; 2016 Jul; 36(1):365-75. PubMed ID: 27121230
[TBL] [Abstract][Full Text] [Related]
8. HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non-Small Cell Lung Cancer.
Yonesaka K; Tanizaki J; Maenishi O; Haratani K; Kawakami H; Tanaka K; Hayashi H; Sakai K; Chiba Y; Tsuya A; Goto H; Otsuka E; Okida H; Kobayashi M; Yoshimoto R; Funabashi M; Hashimoto Y; Hirotani K; Kagari T; Nishio K; Nakagawa K
Clin Cancer Res; 2022 Jan; 28(2):390-403. PubMed ID: 34921025
[TBL] [Abstract][Full Text] [Related]
9. Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells.
Chen J; Bi H; Hou J; Zhang X; Zhang C; Yue L; Wen X; Liu D; Shi H; Yuan J; Liu J; Liu B
Cell Death Dis; 2013 Sep; 4(9):e814. PubMed ID: 24071646
[TBL] [Abstract][Full Text] [Related]
10. Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.
Sato H; Yamamoto H; Sakaguchi M; Shien K; Tomida S; Shien T; Ikeda H; Hatono M; Torigoe H; Namba K; Yoshioka T; Kurihara E; Ogoshi Y; Takahashi Y; Soh J; Toyooka S
Cancer Sci; 2018 Oct; 109(10):3183-3196. PubMed ID: 30098066
[TBL] [Abstract][Full Text] [Related]
11. NOX4 supports glycolysis and promotes glutamine metabolism in non-small cell lung cancer cells.
Zeng C; Wu Q; Wang J; Yao B; Ma L; Yang Z; Li J; Liu B
Free Radic Biol Med; 2016 Dec; 101():236-248. PubMed ID: 27989748
[TBL] [Abstract][Full Text] [Related]
12. Knockdown of KLF5 suppresses hypoxia-induced resistance to cisplatin in NSCLC cells by regulating HIF-1α-dependent glycolysis through inactivation of the PI3K/Akt/mTOR pathway.
Gong T; Cui L; Wang H; Wang H; Han N
J Transl Med; 2018 Jun; 16(1):164. PubMed ID: 29898734
[TBL] [Abstract][Full Text] [Related]
13. MERTK Promotes Resistance to Irreversible EGFR Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancers Expressing Wild-type
Yan D; Parker RE; Wang X; Frye SV; Earp HS; DeRyckere D; Graham DK
Clin Cancer Res; 2018 Dec; 24(24):6523-6535. PubMed ID: 30194074
[TBL] [Abstract][Full Text] [Related]
14. Long non-coding RNA BC087858 induces non-T790M mutation acquired resistance to EGFR-TKIs by activating PI3K/AKT and MEK/ERK pathways and EMT in non-small-cell lung cancer.
Pan H; Jiang T; Cheng N; Wang Q; Ren S; Li X; Zhao C; Zhang L; Cai W; Zhou C
Oncotarget; 2016 Aug; 7(31):49948-49960. PubMed ID: 27409677
[TBL] [Abstract][Full Text] [Related]
15. Thermal treatment decreases resistance to osimertinib in non-small cell lung cancer through the EGFR/PI3K/AKT pathway.
Wang J; Ling X; Zhou M; Ding G; Peng B; Wan J
Neoplasma; 2021 May; 68(3):535-545. PubMed ID: 33724860
[TBL] [Abstract][Full Text] [Related]
16. Marked synergy by vertical inhibition of EGFR signaling in NSCLC spheroids shows SOS1 is a therapeutic target in EGFR-mutated cancer.
Theard PL; Sheffels E; Sealover NE; Linke AJ; Pratico DJ; Kortum RL
Elife; 2020 Sep; 9():. PubMed ID: 32897190
[TBL] [Abstract][Full Text] [Related]
17. PTEN and PI3K/AKT in non-small-cell lung cancer.
Pérez-Ramírez C; Cañadas-Garre M; Molina MÁ; Faus-Dáder MJ; Calleja-Hernández MÁ
Pharmacogenomics; 2015 Nov; 16(16):1843-62. PubMed ID: 26555006
[TBL] [Abstract][Full Text] [Related]
18. Blocking EGFR palmitoylation suppresses PI3K signaling and mutant KRAS lung tumorigenesis.
Kharbanda A; Walter DM; Gudiel AA; Schek N; Feldser DM; Witze ES
Sci Signal; 2020 Mar; 13(621):. PubMed ID: 32127496
[TBL] [Abstract][Full Text] [Related]
19. Targeting the oncogenic MUC1-C protein inhibits mutant EGFR-mediated signaling and survival in non-small cell lung cancer cells.
Kharbanda A; Rajabi H; Jin C; Tchaicha J; Kikuchi E; Wong KK; Kufe D
Clin Cancer Res; 2014 Nov; 20(21):5423-34. PubMed ID: 25189483
[TBL] [Abstract][Full Text] [Related]
20. Reciprocal positive regulation between Cx26 and PI3K/Akt pathway confers acquired gefitinib resistance in NSCLC cells via GJIC-independent induction of EMT.
Yang J; Qin G; Luo M; Chen J; Zhang Q; Li L; Pan L; Qin S
Cell Death Dis; 2015 Jul; 6(7):e1829. PubMed ID: 26203858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]